News|Articles|March 9, 2024

Mood Disorders in Psychiatric Times

Take a look back at our recent coverage relating to our March content theme.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Dose Lithium Once a Day at Night: An Update

ByDavid N. Osser, MD

June 12th 2026

Next Generation Pharmacotherapies for Mood and Anxiety Disorders: An ASCP Poster Presentation Recap

ByAlana King

June 11th 2026

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

ByLeah Kuntz,AJ Cannon, MD

June 10th 2026

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

ByAmit Etkin, MD, PhD

June 9th 2026

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis

ByLeighann Forbes, PhD

June 8th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Mood Disorders in Psychiatric Times

Related Content

Dose Lithium Once a Day at Night: An Update

Next Generation Pharmacotherapies for Mood and Anxiety Disorders: An ASCP Poster Presentation Recap

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

ALTO-203, an H3 Inverse Agonist, in Depression: Biomarker and Pharmacodynamic Findings

Predicting Relapse in Treatment-Resistant Depression: Findings From New Esketamine Analysis

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Monoamines: A Full House

Dose Lithium Once a Day at Night: An Update

Understanding the Complexities of Suicide Risk: A Conversation With Jill Harkavy-Friedman, PhD, and Elizabeth Ballard, PhD

Developing Next-Generation Psychedelic Treatments: Insights on Bretisilocin From AJ Cannon, MD

Consensus on Overcoming Barriers to Long-Acting Injectable Use in Schizophrenia